The healthcare sector recently witnessed a significant acquisition as a major player purchased Verinata Health, Inc. for $1.9 billion. This acquisition highlights the growing importance of diagnostic tools in managing preterm births.
The market for preterm birth diagnostics is characterized by several essential manufacturers, including Qiagen, Hologic Inc., and Medix Biochemica. These companies play a crucial role in developing diagnostic kits that aid in the early detection of preterm birth risks, improving maternal and neonatal health outcomes.
The diagnostic kits market is segmented by product types such as the ffN test, PAMG-1 test, and IGFBP-1 test. It is also categorized by sample types, including blood, urine, and vaginal discharge.
The end-users of these diagnostic tools primarily consist of hospitals, diagnostic laboratories, outpatient clinics, and research centers.
The market for preterm birth prevention and management is projected to reach a valuation of $1.70 billion by 2024 and exceed $4.49 billion by 2034, with a compound annual growth rate (CAGR) of 10.2%.
The preterm birth and prom testing market is expected to grow from approximately $1.7 billion in 2021 to nearly $2.5 billion by the end of 2032, with a projected CAGR of 3.2% over the next decade.
The medical telepresence robots market is also experiencing notable growth, projected to reach $70.5 million in 2024 and grow to $110.5 million by 2034, with a CAGR of 4.4%.
The global reagent filling systems market is projected to be worth $10,253.6 million in 2024 and rise to $18,190.1 million by 2034, with a CAGR of 5.9%.
The compression veterinary bandages market is anticipated to reach $161.1 million by 2033, growing at a CAGR of 3.2% from an estimated $117.0 million in 2023.
Source: Sabyasachi Ghosh, Associate Vice President at Future Market Insights, Inc.